Danish biotech Saniona recently presented positive topline results from a clinical phase II study in hypothalamic obesity (HO), one of several rare eating disorders and obesity related indications the company is currently pursuing. BioStock connected with CEO Rami Levin in Boston, for a video interview in which he expands on the HO study results, Saniona’s financing strategy and the next steps required to drive the primary asset Tesomet towards commercialization.

Watch the full interview below.

 

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev